U.S. Market Wrap

Amgen (AMGN) Q2 2026: Prolia Falls 32%, Growing Products Add $1.5B

Amgen's newer medicines outgrew its collapsing legacy franchises by roughly two to one this quarter. Products in decline shed $765 million of quarterly sales year over year, led by a 32.4% drop in Prolia and a 33.8% drop in XGEVA; growing products added $1,531 million in product revenue across Repatha, EVENITY, TEZSPIRE and newer launches. Total Q2 revenue reached $10,054 million, clearing $10 billion for the first time.